Shares of Arcus Biosciences Inc. RCUS, -27.76% were down 17.2% in premarket trading on Tuesday, the day after the company said the experimental treatment for metastatic non-small cell lung cancer that...
Shares of Arcus Biosciences Inc. RCUS, -27.76% were down 17.2% in premarket trading on Tuesday, the day after the company said the experimental treatment for metastatic non-small cell lung cancer that...